People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Precipio, Inc. | — | Biotechnology | Series B | $67.0M | $32.2M | 2010 |
| Trovagene, Inc. | — | Biotechnology | Series A | $45.3M | $488.0M | 2009 |
| Sorrento Therapeutics, Inc. | — | Biotechnology | Series A | $19.8M | $66.9M | 2009 |
| selectIon, Inc. | — | Biotechnology | Series A | $19.6M | $16.1M | 2019 |
| Sorrento Therapeutics, Inc. | — | Biotechnology | Seed | $2.3M | $102.1M | 2009 |
Antonius Schuh at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Antonius Schuh on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steve Zaniboni | 3 | 3 |
| Henry Ji | 2 | 5 |
| Rodney Markin | 2 | 4 |
| RODNEY S MARKIN | 2 | 3 |
| David Cohen | 1 | 38 |
| Michael Foster | 1 | 8 |
| Cam Gallagher | 1 | 7 |
| John Brancaccio | 1 | 5 |
| Paul Billings | 1 | 5 |
| Michael Luther | 1 | 4 |
| Lewis J. Shuster | 1 | 4 |
| Curtis Lockshin | 1 | 3 |
| Glenn L. Halpryn | 1 | 3 |
| Richard G Vincent | 1 | 3 |
| Doug Fisher | 1 | 3 |
| Gary S. Jacob | 1 | 3 |
| Thomas Adams | 1 | 3 |
| Gary Jacob | 1 | 3 |
| John P. Brancaccio | 1 | 3 |
| Gary W. Pace | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.